Aclaris Therapeutics, Inc. Q1 FY2024 earnings call

Neal Walker announced that Aclaris is moving ATI-2138 forward in a proof-of-concept study for moderate to severe atopic dermatitis. Joe Monahan discussed ATI-2138 as a covalent inhibitor targeting ITK and JAK3, highlighting its unique pharmacology, preclinical activity in various disease models, and positive Phase 1 study results supporting advancement to Phase 2. Aclaris is expanding efforts in the ITK pathway with discovery of next-generation ITK inhibitors. Kevin Balthaser mentioned the company has a strong balance sheet with $161 million in cash, cash equivalents, and marketable securities at the end of Q1 2024, and cost containment initiatives are on track.

The first indication for ATI-2138 is a proof-of-concept Phase 2 study in moderate to severe atopic dermatitis, an open-label 12-week, 15-patient study to assess safety, PK, and early efficacy. Neal Walker mentioned the Phase 2a study for atopic dermatitis is underway, with top-line data expected within a year of the call.

Forward-looking statements involve risks, changes in circumstances, assumptions, and uncertainties, as described in the company's Form 10-K and other SEC filings.

Q: Roger Song asked about the synergistic effects of ITK and JAK3 inhibition in preclinical models and PD markers in Phase 2.

A: Neal Walker and Joe Monahan discussed preclinical synergy and plans to use PD markers in Phase 2.

Q: Thomas Smith asked about Phase 2a trial design, open-label vs. placebo, and study start timeline.

A: Neal Walker explained open-label design for speed and enrollment, with top-line data expected within a year.

Q: Omari asked about funding for the proof-of-concept study and unmet need in atopic dermatitis.

A: Neal Walker stated the study is funded and discussed unmet need in the atopic dermatitis space.

Q: Julian Harrison asked about IP portfolio related to JAK inhibitors for alopecia.

A: Neal Walker discussed the IP portfolio and royalty deals with Lilly and Sun Pharma.

Q: Alex Thompson asked about differentiation from Pfizer's compound and black box warnings.

A: Joe Monahan explained ATI-2138's differentiation from ritlecitinib and discussed black box warnings.

Q: Gavin Clark-Gartner asked about safety profile view by providers.

A: Neal Walker discussed provider views on safety and patient benefits.